- Home
- MHI vs MRSN Comparison
MHI vs MRSN Comparison
Compare MHI & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHI
- MRSN
- Stock Information
- Founded
- MHI 2003
- MRSN 2001
- Country
- MHI United States
- MRSN United States
- Employees
- MHI N/A
- MRSN N/A
- Industry
- MHI Investment Managers
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- MHI Finance
- MRSN Health Care
- Exchange
- MHI Nasdaq
- MRSN Nasdaq
- Market Cap
- MHI N/A
- MRSN 224.5M
- IPO Year
- MHI N/A
- MRSN 2017
- Fundamental
- Price
- MHI $9.60
- MRSN $2.02
- Analyst Decision
- MHI
- MRSN Buy
- Analyst Count
- MHI 0
- MRSN 6
- Target Price
- MHI N/A
- MRSN $6.00
- AVG Volume (30 Days)
- MHI 98.8K
- MRSN 1.0M
- Earning Date
- MHI 01-01-0001
- MRSN 11-05-2024
- Dividend Yield
- MHI 4.09%
- MRSN N/A
- EPS Growth
- MHI N/A
- MRSN N/A
- EPS
- MHI 0.04
- MRSN N/A
- Revenue
- MHI N/A
- MRSN $29,937,000.00
- Revenue This Year
- MHI N/A
- MRSN N/A
- Revenue Next Year
- MHI N/A
- MRSN $7.15
- P/E Ratio
- MHI $219.25
- MRSN N/A
- Revenue Growth
- MHI N/A
- MRSN N/A
- 52 Week Low
- MHI $6.93
- MRSN $1.07
- 52 Week High
- MHI $9.05
- MRSN $6.28
- Technical
- Relative Strength Index (RSI)
- MHI 57.37
- MRSN 58.27
- Support Level
- MHI $9.62
- MRSN $1.79
- Resistance Level
- MHI $9.65
- MRSN $2.18
- Average True Range (ATR)
- MHI 0.07
- MRSN 0.16
- MACD
- MHI -0.01
- MRSN -0.00
- Stochastic Oscillator
- MHI 36.84
- MRSN 49.00
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.